RBC Capital Cite GH Research PLC's (GHRS) Long-Term Sales Potential Following Psychedelics Symposium
TheFly reported that on January 23, RBC Capital raised its price target on GHRS to $40 from $33 and maintained an Outperform rating.
Gh Research Plc (GHRS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Lynx1 Capital Management Weston Nichols | 10,406,575 | $132,163,502 | +21% | 26.75% |
| 2. | Biotechnology Value Fund / BVF Inc Mark Lampert | 8,827,712 | $112,111,942 | 3.77% | |
| 3. | RA Capital Management Peter Kolchinsky | 7,676,697 | $97,494,052 | 1% | |
| 4. | VenBio Select Advisor Kurt Von Emster | 1,800,000 | $22,860,000 | 0.22% | |
| 5. | Cormorant Asset Management Bihua Chen | 1,300,000 | $16,510,000 | -33% | 0.76% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,933,815 | $75,359,451 | 0.75% | |
| 2. | 5,136,045 | $65,227,771 | 0% | |
| 3. | 673,735 | $8,556,435 | 0.03% | |
| 4. | 572,665 | $7,272,846 | 2.29% | |
| 5. | 434,401 | $5,516,893 | 0% |
News See All
7 Most Promising Psychedelic Stocks According to Hedge Funds
The psychedelic industry is poised to have a significant "second wave," transforming from a speculative, counterculture-driven movement into a recognized cornerstone of the US healthcare system.
GH Research PLC (GHRS) Reports 73% Remission in Phase 2b Depression Trial
GH Research PLC (NASDAQ:GHRS) is a clinical-stage biopharmaceutical company developing innovative therapies for treatment-resistant depression (TRD) and other psychiatric and neurological disorders.
13 Best Psychedelic Stocks to Invest in Now
Unlike drugs such as cocaine or marijuana, psychedelics create an “alternate reality” by altering feelings, thoughts, and energy levels.
GH Research Responds to FDA Clinical Hold on Depression Treatment GH001 Ahead of Schedule
GH Research (NASDAQ:GHRS) is one of the best-performing NASDAQ stocks according to analysts.
Cantor Fitzgerald Initiates Coverage of GH Research (GHRS) With Overweight Rating
The analysts are supporting the company’s potential in the broader mental health sector, demonstrating the transformative impact of psychedelics on numerous mental health disorders, including depression...
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025
No matter the market environment, you’ll always find entertainment in the biotech space.
12 Best Psychedelic Stocks to Buy in 2025
In contrast to drugs like cocaine or marijuana, psychedelics are strong and give users access to a kind of "alternate reality." One class of hallucinogenic substances that can produce unusual states of...
12 Best Performing Small Cap Stocks So Far in 2025
On February 14, Stacey Sears, portfolio manager at Emerald Advisors, joined 'Squawk Box' on CNBC to share her insights on the market's performance in early February.
Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025
The healthcare sector is staging a comeback so far in 2025 after two years of underperformance. These stocks could get even hotter due to AI.
Hedge Fund Resource Center Billionaire Hedge Funds
